24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension

Journal of Human Hypertension

Volumn 25, Issue 10, 2011, Pages 615-622

  Lacourciere Y ^a   Crikelair, N ^b   Glazer, R D ^b   Yen, J ^b   Calhoun, D A ^c  

^a LAVAL UNIVERSITY   (Canada)

^b NOVARTIS PHARMA AG   (Switzerland)

^c University of Alabama at Birmingham   (United States)

Author keywords

amlodipine; hydrochlorothiazide; triple therapy; valsartan

Indexed keywords

AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS VALSARTAN; AMLODIPINE PLUS HYDROCHLORTHIAZIDE PLUS VALSARTAN; AMLODIPINE PLUS VALSARTAN; ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 80052872817     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.115     Document Type: Article

References (32)

1. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet 1978; 1: 795-797.
2. Gosse P, Schumacher H. Early morning blood pressure surge. J Clin Hypertens (Greenwich) 2006; 8: 584-589.
3. Leppäluoto J, Ruskoaho H. Atrial natriuretic peptide, renin activity, aldosterone, urine volume and electrolytes during a 24-h sleep-wake cycle in man. Acta Physiol Scand 1990; 139: 47-53. (Pubitemid 20161191)
4. Veerman DP, Imholz BP, Wieling W, Wesseling KH, van Montfrans GA. Circadian profile of systemic hemo-dynamics. Hypertension 1995; 26: 55-59.
5. Sica DA. What are the influences of salt, potassium, the sympathetic nervous system, and the renin-angiotensin system on the circadian variation in blood pressure? Blood Press Monit 1999; 4(Suppl 2): S9-S16.
6. Lamarre-Cliche M, de Champlain J, Lacourcière Y, Poirier L, Karas M, Larochelle P. Effects of circadian rhythms, posture, and medication on renin-aldoster-one interrelations in essential hypertensives. Am J Hypertens 2005; 18: 56-64. (Pubitemid 40187350)
7. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999; 12: 205S-213S. (Pubitemid 30029273)
8. Redon J, Roca-Cusachs A, Mora-Macia J. Uncontrolled early morning blood pressure in medicated patients: the ACAMPA study. Analysis of the control of blood pressure using ambulatory blood pressure monitoring. Blood Press Monit 2002; 7: 111-116.
9. Polónia J, Alcantâra P, Amado P, Silva JA, Nazaré J, Braz-Nogueira J et al. Lack of adequate blood pressure control in the morning and evening periods in medicated hypertensive patients considered to be controlled in the office. Rev Port Cardiol 2005; 24: 1059-1072. (Pubitemid 41674248)
10. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4: 393-404. (Pubitemid 35469393)
11. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. (Pubitemid 34286536)
12. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289: 2073-2082. (Pubitemid 37430209)
13. Milani RV. Reaching for aggressive blood pressure goals: role of angiotensin receptor blockade in combination therapy. Am J Manag Care 2005; 11(7 Suppl): S220-S227. (Pubitemid 41361629)
14. Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431. (Pubitemid 35340538)
15. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816. (Pubitemid 37509488)
16. Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, M a n c i a G et al. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Am Heart J 2008; 156: 241-247. (Pubitemid 352020399)
17. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V et al. Benazepril plus amlodipine or hydrochlor-othiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.
18. Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009; 54: 32-39.
19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252. (Pubitemid 37553153)
20. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187. (Pubitemid 46924065)
21. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328: 634-640. (Pubitemid 38340037)
22. Ommen ES, Lipkowitz MS. The role of ambulatory BP monitoring in clinical care. Geriatrics 2007; 62: 11-14. (Pubitemid 47311385)
23. Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens 2008; 26: 1290-1299.
24. Staessen JA, Beilin L, Parati G, Waeber B, White W. Task force IV: clinical use of ambulatory blood pressure monitoring. Participants of the 1999 Consensus Conference on ambulatory blood pressure monitoring. Blood Press Monit 1999; 4: 319-331.
25. White WB. Importance of blood pressure control over a 24-hour period. J Manag Care Pharm 2007; 13(8 Suppl B): 34-39.
26. Lacourcière Y, Wright Jr JT, Samuel R, Zappe D, Purkayastha D, Black HR. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hy-drochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. Blood Press Monit 2009; 14: 112-120.
27. Lacourcière Y, Gil-Extremera B, Mueller O, Byrne M, Williams L. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003; 57: 273-279. (Pubitemid 36700710)
28. Lacourcière Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlor-othiazide 40/12.5 mg and 80/12.5mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin Ther 2005; 27: 1795-1805. (Pubitemid 41815230)
29. Neutel JM, Smith D. Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/ hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension. J Int Med Res 2005; 33: 620-631. (Pubitemid 43012617)
30. Neldam S, Edwards C. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol 2006; 15: 151-160.
31. Minami J, Abe C, Akashiba A, Takahashi T, Kameda T, Ishimitsu T et al. Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothia-zide in patients with uncontrolled hypertension. Int Heart J 2007; 48: 177-186. (Pubitemid 46592756)
32. Sharma AM, Davidson J, Koval S, Lacourcière Y. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol 2007; 6: 28.